NEW YORK (GenomeWeb) – Cancer Genetics said today that New York State has approved the company's Focus::Myeloid next-generation sequencing-based panel for myeloid malignancies.

The 54-gene panel provides information that clinicians can use to diagnose, provide prognosis, determine treatment options, and provide risk stratification for patients with acute myeloid leukemia, myelodysplastic syndrome, and myeloproliferative neoplasms, the company said.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

The London School of Economics' Daniele Fanelli argues at the Proceedings of the National Academy of Sciences that the reproducibility crisis in science isn't as dire as some say.

A team of researchers in Portugal has examined the genomic basis for racing pigeons' athleticism and navigational skills, finding it's likely polygenic.

Wired reports that diagnostic firms continue to seek, post-Theranos, the ability to diagnose diseases from small amounts of blood.

In Science this week: analysis of DNA from ancient North Africans, and more.